Stock Analiz

Crescent Biopharma, Inc. CBIO

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$14.15Market cap $550M
Open the interactive analysis →

Crescent Biopharma, Inc. (CBIO) is a healthcare company listed in the US with a market value of about $550M. In the twelve months to September 30, 2026 it had revenue of $15M and net income of -$178M, a net margin of -1188.3%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 1% a year, a 5-year average ROIC of -85%.

About Crescent Biopharma

Crescent Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $15M in 2014 to $11M in 2025, a decline of about 2.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 26% over three years (buybacks). It spends 1273% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S36.7
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-15.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)1.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-109500.0%
ROIC (5-yr avg.)-85.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$15M$11M—$10000$75000$1M$10M———$18500
Net income-$178M-$154M-$38M-$37M-$47M-$63M-$51M-$58M-$48M-$33M-$32M
Free cash flow-$82M-$72M-$31M-$35M-$47M-$58M-$39M-$52M-$43M-$30M-$30M
EPS (diluted)$-7.29$-3.96$-0.59$-0.58$-0.89$-1.23$-1.12$-1.34$-1.18$-1.13$-1.50
Net margin-1188.3%-1419.6%—-369000.0%-62251.7%-5469.0%-502.1%———-171900.0%
ROIC—-58.9%-143.3%-79.1%-85.4%-60.0%-31.1%-30.7%-19.4%-22.4%-71.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $32.33, 129% above the current price; targets range from $28.00 to $40.00; the consensus rating is “Strong buy”; expected EPS is $-2.76 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Crescent Biopharma pay a dividend?

Not currently.

Is Crescent Biopharma a good stock to buy?

We do not give buy or sell advice. Crescent Biopharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.